Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection

Schaller M, Borelli C, Berger U, Walker B, Schmidt S, Weindl G, Jaeckel A (2009)
MEDICAL MYCOLOGY 47(7): 753-758.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Schaller, Martin; Borelli, Claudia; Berger, UrsulaUniBi; Walker, Birgit; Schmidt, Sybille; Weindl, Guenther; Jaeckel, Andreas
Abstract / Bemerkung
Antimycotic nail lacquers are effective and safe for the treatment of onychomycosis. To assess the efficacy of three topical agents we studied the minimum inhibitory and fungicidal concentration of amorolfine, bifonazole and ciclopiroxolamine. Amorolfine showed the most effective fungistatic and fungicidal activity in vitro against seven clinical Trichophyton rubrum nail isolates, followed in descending order by ciclopiroxolamine and bifonazole. To mimic a nail infection more appropriately, the nail minimum fungicidal concentration (Nail-MFC) was determined in an onychomycosis model. Amorolfine and ciclopiroxolamine had Nail-MFCs ranging from 2-32 mu g/ml and 16-32 mu g/ml, respectively. In contrast, bifonazole was unable to kill T. rubrum in this model. Statistical analyses of the results show a significant difference between the two treatments with amorolfine and ciclopiroxolamine (P < 0.001). For amorolfine a mean concentration of 12.28 mu g/ml (95%-CI = [8.66, 17.41]) was sufficient to kill all strains, while for ciclopiroxolamine about twice that concentration was needed, i.e., 24.13 mu g/ml (95%-CI = [17.06, 34.13]). The individual sensitivity of six of the seven T. rubrum strains was higher for amorolfine. These data demonstrate that both amorolfine and ciclopiroxolamine effectively kill T. rubrum growing on nail powder and suggest a better cidal action for amorolfine. Further investigation would be required to determine if these in vitro data can partially explain the clinical observation of significantly higher cure rates in onychomycosis following a therapy with an amorolfine-containing nail lacquer formulation.
Stichworte
ciclopiroxolamine; Trichophyton rubrum; onychomycosis; nail infection; in vitro; Amorolfine; bifonazole
Erscheinungsjahr
2009
Zeitschriftentitel
MEDICAL MYCOLOGY
Band
47
Ausgabe
7
Seite(n)
753-758
ISSN
1369-3786
eISSN
1460-2709
Page URI
https://pub.uni-bielefeld.de/record/1589484

Zitieren

Schaller M, Borelli C, Berger U, et al. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. MEDICAL MYCOLOGY. 2009;47(7):753-758.
Schaller, M., Borelli, C., Berger, U., Walker, B., Schmidt, S., Weindl, G., & Jaeckel, A. (2009). Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. MEDICAL MYCOLOGY, 47(7), 753-758. https://doi.org/10.3109/13693780802577892
Schaller, Martin, Borelli, Claudia, Berger, Ursula, Walker, Birgit, Schmidt, Sybille, Weindl, Guenther, and Jaeckel, Andreas. 2009. “Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection”. MEDICAL MYCOLOGY 47 (7): 753-758.
Schaller, M., Borelli, C., Berger, U., Walker, B., Schmidt, S., Weindl, G., and Jaeckel, A. (2009). Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. MEDICAL MYCOLOGY 47, 753-758.
Schaller, M., et al., 2009. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. MEDICAL MYCOLOGY, 47(7), p 753-758.
M. Schaller, et al., “Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection”, MEDICAL MYCOLOGY, vol. 47, 2009, pp. 753-758.
Schaller, M., Borelli, C., Berger, U., Walker, B., Schmidt, S., Weindl, G., Jaeckel, A.: Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. MEDICAL MYCOLOGY. 47, 753-758 (2009).
Schaller, Martin, Borelli, Claudia, Berger, Ursula, Walker, Birgit, Schmidt, Sybille, Weindl, Guenther, and Jaeckel, Andreas. “Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection”. MEDICAL MYCOLOGY 47.7 (2009): 753-758.

25 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Potential of Chemical and Physical Enhancers for Transungual Delivery of Amorolfine Hydrochloride.
Šveikauskaitė I, Pockevičius A, Briedis V., Materials (Basel) 12(7), 2019
PMID: 30925734
Antifungal Drug Susceptibility Testing of Dermatophytes: Laboratory Findings to Clinical Implications.
Dogra S, Shaw D, Rudramurthy SM., Indian Dermatol Online J 10(3), 2019
PMID: 31149563
Outstanding personalities in German-speaking mycology : Dedicated to Professor Dr. Johannes Müller.
Seebacher C, Lotti T, Roccia MG, Fioranelli M, Wollina U., Wien Med Wochenschr 167(suppl 1), 2017
PMID: 28233077
Emergence of nail lacquers as potential transungual delivery system in the management of onchomycosis.
Kataria P, Sharma G, Thakur K, Bansal V, Dogra S, Katare OP., Expert Opin Drug Deliv 13(7), 2016
PMID: 27054394
Efficacy of antifungal PACT in an in vitro model of onychomycosis.
Mehra T, Schaller M, Walker B, Braunsdorf C, Mailänder-Sanchez D, Schynowski F, Hahn R, Röcken M, Köberle M, Borelli C., J Eur Acad Dermatol Venereol 29(1), 2015
PMID: 24661404
Development of a novel in vitro onychomycosis model for the evaluation of topical antifungal activity.
Sleven R, Lanckacker E, Boulet G, Delputte P, Maes L, Cos P., J Microbiol Methods 112(), 2015
PMID: 25772040
Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success.
Pollak RA, Siu WJJ, Tatsumi Y, Pillai R., J Fungi (Basel) 1(2), 2015
PMID: 29376902
Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
Seidl HP, Jäckel A, Müller J, Schaller M, Borelli C, Polak A., Mycoses 58(10), 2015
PMID: 26334024
Comparison of user-friendliness and treatment cost of Loceryl® vs. Ciclopoli®--a patient's perspective.
Schaller M, Braunsdorf C, Mailänder-Sanchez D, Jäckel A, Müller J, Borelli C., Mycoses 58(10), 2015
PMID: 26393437
In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes.
Tamura T, Asahara M, Yamamoto M, Yamaura M, Matsumura M, Goto K, Rezaei-Matehkolaei A, Mirhendi H, Makimura M, Makimura K., Microbiol Immunol 58(1), 2014
PMID: 24215461
The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K, Sugimoto N, Hosaka S, Katafuchi-Nagashima M, Arakawa Y, Tatsumi Y, Jo Siu W, Pillai R., Antimicrob Agents Chemother 58(7), 2014
PMID: 24752277
Antifungal activity of nanocapsule suspensions containing tea tree oil on the growth of Trichophyton rubrum.
Flores FC, de Lima JA, Ribeiro RF, Alves SH, Rolim CM, Beck RC, da Silva CB., Mycopathologia 175(3-4), 2013
PMID: 23392821
Contact-free inactivation of Trichophyton rubrum and Microsporum canis by cold atmospheric plasma treatment.
Heinlin J, Maisch T, Zimmermann JL, Shimizu T, Holzmann T, Simon M, Heider J, Landthaler M, Morfill G, Karrer S., Future Microbiol 8(9), 2013
PMID: 24020738
New therapeutic options for onychomycosis.
Gupta AK, Simpson FC., Expert Opin Pharmacother 13(8), 2012
PMID: 22533461
An update on treatment of onychomycosis.
Grover C, Khurana A., Mycoses 55(6), 2012
PMID: 22540995
Do you know this syndrome?
Costella TM, Romiti N, Almeida JR, Dinato SL, Sementilli A, Ciofi TP., An Bras Dermatol 86(4), 2011
PMID: 21987162
Comparative evaluation of effectivity and safety of topical amorolfine and clotrimazole in the treatment of tinea corporis.
Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay DN., Indian J Dermatol 56(6), 2011
PMID: 22345765

21 References

Daten bereitgestellt von Europe PubMed Central.

Epidemiology and clinical classification of onychomycosis.
Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R; European Onychomycosis Observatory., J Eur Acad Dermatol Venereol 19 Suppl 1(), 2005
PMID: 16120199
Treatment of onychomycosis: pros and cons of antifungal agents.
Gupta AK, Ryder JE, Skinner AR., J Cutan Med Surg 8(1), 2004
PMID: 15688097
Treatment options--development of consensus guidelines.
Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R; Taskforce on Onychomycosis Education., J Eur Acad Dermatol Venereol 19 Suppl 1(), 2005
PMID: 16120203
New insights into the effect of amorolfine nail lacquer.
Flagothier C, Pierard-Franchimont C, Pierard GE., Mycoses 48(2), 2005
PMID: 15743424
In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer.
Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone MF, Mailland F., Drug Dev Ind Pharm 31(1), 2005
PMID: 15704853
Ciclopirox nail lacquer solution 8% in the 21st century.
Gupta AK, Baran R., J. Am. Acad. Dermatol. 43(4 Suppl), 2000
PMID: 11051138
Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis.
Bonifaz A, Guzman A, Garcia C, Sosa J, Saul A., Int. J. Dermatol. 34(7), 1995
PMID: 7591419
Antifungal drug response in an in vitro model of dermatophyte nail infection.
Osborne CS, Leitner I, Favre B, Ryder NS., Med. Mycol. 42(2), 2004
PMID: 15124869
In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China.
Li RY, Wan Z, Wang AP, Shen YN, Lu CM, Li M, Xi LY, Liu WD, Zeng FQ., Mycoses 47(9-10), 2004
PMID: 15504124
Antimycotic efficacy of bifonazole in vitro and in vivo.
Plempel M, Regel E, Buchel KH., Arzneimittelforschung 33(4), 1983
PMID: 6683530
Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay.
Favre B, Hofbauer B, Hildering KS, Ryder NS., J. Clin. Microbiol. 41(10), 2003
PMID: 14532230
Ciclopirox delivery into the human nail plate.
Hui X, Wester RC, Barbadillo S, Lee C, Patel B, Wortzmman M, Gans EH, Maibach HI., J Pharm Sci 93(10), 2004
PMID: 15349963
Kinetics of amorolfine in human nails.
Polak A., Mycoses 36(3-4), 1993
PMID: 8366874

Halmy, J Eur Acad Dermatol Venereol 18(1), 2004
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 19888808
PubMed | Europe PMC

Suchen in

Google Scholar